8 completed, 3 recruiting, 2 active not recruiting, 2 not yet recruiting. 18 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 8, Recruiting 3, Active not recruiting 2, Not yet recruiting 2, Unknown 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Pulmonary Tuberculosis: new trials by email Literature Review of Pulmonary Tuberculosis trials Research Report on Pulmonary Tuberculosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort BLMZ - Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Not yet recruiting | Beijing Chest Hospital | 120 | 2025-12-01 | 2025-12-08 |
| Ultra-Short Regimen for Elderly DS-TB Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Not yet recruiting | Shenzhen Third People's Hospital | 300 | 2025-07-25 | 2025-07-22 |
| A PAN-USR TB Multi-Center Trial Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Recruiting | Shenzhen Third People's Hospital | 610 | 2025-06-18 | 2025-12-01 |
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort bedaquiline, delamanid, linezolid - Drug-resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Active not recruiting | Huashan Hospital | 120 | 2024-11-27 | 2025-09-02 |
| Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial 4-month regimen (2HERZ/2HRE), 6-month (2HERZ/4HRE) - Pulmonary Tuberculosis | Phase 3 | Recruiting | Kaohsiung Veterans General Hospital. | 270 | 2024-01-01 | 2026-08-03 |
| Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort Bedaquiline, Delamanid, Contezolid - Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis | Phase 3 | Active not recruiting | Beijing Chest Hospital | 186 | 2023-12-22 | 2025-04-01 |
| Novel Triple-dose Tuberculosis Retreatment Regimen 6EH³R³Z, 6EHRZ - Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Recruiting | Institute of Tropical Medicine, Belgium | 370 | 2021-03-01 | 2025-04-13 |
| PRACTECAL-PKPD Sub Study Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Unknown | Medecins Sans Frontieres, Netherlands | 240 | 2019-08-06 | 2021-05-14 |
| A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis Rifampicin, Isoniazid, Ethambutol - Pulmonary Tuberculosis | Phase 3 | Completed | St George's, University of London | 672 | 2017-02-01 | 2023-04-27 |
| A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB Bedaquiline, PA-824, Linezolid - Pulmonary Tuberculosis | Phase 3 | Completed | Global Alliance for TB Drug Development | 109 | 2015-03-01 | 2025-09-08 |
| Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis Isoniazid with HUEXC030 and RZE, HRZE - Pulmonary Tuberculosis | Phase 2 / Phase 3 | Completed | Orient Pharma Co., Ltd. | 557 | 2012-12-06 | 2022-06-15 |
| Latency in Pulmonary Tuberculosis Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol - Pulmonary Tuberculosis | Phase 3 | Completed | Tuberculosis Research Centre, India | 120 | 2010-02-01 | 2021-04-19 |
| A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients A. 100,000 IU Cholecalciferol per dose of 3.3ml, B. Migliol Oil without Cholecalciferol - Pulmonary Tuberculosis | Phase 3 | Completed | Peter Daley | 250 | 2009-11-01 | 2012-07-06 |
| Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2) isoniazid - Pulmonary Tuberculosis | Phase 3 | Terminated | University of Cologne | 900 | 2008-06-01 | 2011-02-28 |
| Efficacy of Oral Zinc Administration as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients Zinc supplement, Placebo - Pulmonary Tuberculosis | Phase 3 | Unknown | Ministry of Science and Technology, India | 150 | 2008-02-01 | 2009-09-15 |
| Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin - Pulmonary Tuberculosis | Phase 3 | Completed | Global Alliance for TB Drug Development | 1931 | 2008-01-01 | 2017-03-21 |
| Vitamin A Therapy for Tuberculosis multivitamin - Pulmonary Tuberculosis, HIV Infections | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1140 | 1998-09-01 | 2007-09-18 |
| TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis Rifapentine, Isoniazid - Pulmonary Tuberculosis | Phase 3 | Completed | Centers for Disease Control and Prevention | 1000 | 1995-04-01 | 2005-09-05 |
Tuberculosis, Pulmonary (18) · Tuberculosis (5) · Tuberculosis, Multidrug-Resistant (5) · Extensively Drug-Resistant Tuberculosis (2) · HIV Infections (1)
Actinomycetales Infections (18) · Bacterial Infections (18) · Bacterial Infections and Mycoses (18) · Gram-Positive Bacterial Infections (18) · Infections (18) · Lung Diseases (18) · Mycobacterium Infections (18) · Respiratory Tract Diseases (18) · Respiratory Tract Infections (18) · Tuberculosis (13) · Blood-Borne Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1)
Isoniazid (9) · Ethambutol (7) · Linezolid (6) · Pyrazinamide (6) · bedaquiline (6) · Moxifloxacin (5) · Rifampin (5) · Clofazimine (3) · pretomanid (3) · Levofloxacin (2) · OPC-67683 (2) · Protons (2) · sitafloxacin (2) · Aminosalicylic Acid (1) · Cholecalciferol (1)
Beijing Chest Hospital (2) · Global Alliance for TB Drug Development (2) · Shenzhen Third People's Hospital (2) · Centers for Disease Control and Prevention (1) · Huashan Hospital (1) · Institute of Tropical Medicine, Belgium (1) · Kaohsiung Veterans General Hospital. (1) · Medecins Sans Frontieres, Netherlands (1) · Ministry of Science and Technology, India (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Orient Pharma Co., Ltd. (1) · Peter Daley (1) · St George's, University of London (1) · Tuberculosis Research Centre, India (1) · University of Cologne (1)
China (5) · India (4) · South Africa (3) · Taiwan (2) · Belarus (1) · Botswana (1) · Bulgaria (1) · Canada (1) · Germany (1) · Guinea (1) · Kenya (1) · Malawi (1) · Malaysia (1) · Mexico (1) · Nepal (1)
A K Jain, MBBS FICA (1) · Alexander Pym, MB BMRCP PhD (1) · Ali Zumla, BSc MBChB MSc PhD (1) · Amina Jindani, MD (1) · Andreas Diacon, BM MD (1) · Andrew Nunn, BSc MSc (1) · Angela Crook (1) · Anjula Bhargava, MS (1) · Arun Aggarwal, MD (1) · Ashish Rohatgi, DTCD (1) · Ashok K Singh, MD, FCCP, FCCS (1) · Aziah Mahayiddin, MD (1) · Bern Nyang'wa, MB BS, MPH (1) · Bhanu P Singh, MD, FCCP (1) · Chandra P Singh, MD (1)
PMID 36808186, PMID 17705950, PMID 20610636, PMID 25196020, PMID 25363329, PMID 25863562, PMID 26038418, PMID 26095067, PMID 26104205, PMID 26847437, PMID 29779774, PMID 32130813, PMID 34489274, PMID 34604901, PMID 36053506, PMID 36546625, PMID 36804834, PMID 37567554, PMID 37980911, PMID 37986887, PMID 38320155, PMID 38468320, PMID 41917253, PMID 42270675